Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.51 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5980703 | 1.00 | ADORA3 (0.55) | ADORA3ADORA2AHSPA5HSPA8HIF1A | |
| SCHEMBL658006 | 0.89 | ADORA3 (0.67) | ADORA3ADORA2AHSPA5HSPA8HIF1A | |
| SCHEMBL5982454 | 0.89 | ADORA3 (0.67) | ADORA3ADORA2AHSPA5HSPA8HIF1A | |
| SCHEMBL658005 | 0.89 | ADORA3 (0.67) | ADORA3ADORA2AHSPA5HSPA8HIF1A | |
| SCHEMBL5982465 | 0.89 | ADORA3 (0.67) | ADORA3ADORA2AHSPA5HSPA8HIF1A | |
| SCHEMBL5982757 | 0.88 | ADORA3 (0.55) | ADORA3ADORA2AHSPA5HSPA8HIF1A | |
| SCHEMBL5982751 | 0.88 | ADORA3 (0.55) | ADORA3ADORA2AHSPA5HSPA8HIF1A | |
| SCHEMBL5983124 | 0.88 | ADORA3 (0.52) | ADORA3ADORA2AHIF1APNPLMNA | |
| SCHEMBL31685786 | 0.88 | ADORA3 (0.52) | ADORA3ADORA2AHIF1APNPLMNA | |
| SCHEMBL5983113 | 0.88 | ADORA3 (0.52) | ADORA3ADORA2AHIF1APNPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507873-A4 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | CYGENE INC (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060008813-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ERITJA RAMON | 2006-01-12 | — | — | US | disclosed |
| EP-1228243-A4 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | CYGENE INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1507873-A1 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | Cygene, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050014164-A1 | Triplex-forming oligonucleotides containing modified purines and their applications | ERITJA RAMON (ES) | 2005-01-20 | — | — | US | disclosed |
| US-6831072-B2 | Such as 8-amino-2'deoxyadenosine by treating 8-azido-2'deoxyadenosine with aqueous solution of methylamine or dimethylamine; for targeting nucleic acids without amplification and less use of enzymes | CYGENE, INC. | 2004-12-14 | — | — | US | disclosed |
| WO-2004037981-A2 | TRIPLEX-FORMING OLIGONUCLEOTIDES CONTAINING MODIFIED PURINES AND THEIR APPLICATIONS | CYGENE LABORATORIES, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040029160-A1 | Parallel stranded duplexes of deoxyribonucleic acid and methods of use | CYGENE, INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003100099-A1 | PARALLEL STRANDED DUPLEXES OF DEOXYRIBONUCLEIC ACID AND METHODS OF USE | CYGENE, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | CYGENE, INC. | 2003-07-17 | — | — | US | disclosed |
| EP-1228243-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | Cygene, Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032924-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | CYGENE, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ADAR, NSUN2, RNGTT | ADORA3 324/4885ADORA2A 145/4885HSPA5 2122/4885 |
| US-20040029160-A1 | Parallel stranded duplexes of deoxyribonucleic acid and methods of use | DDX18, DDX1, ADAR | ADORA3 437/4885ADORA2A 250/4885HSPA5 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.